Lv2
170 积分 2023-08-04 加入
Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir
1小时前
求助中
lenacapavir licenses will not delivery on all opportunities
1小时前
求助中
Twice-yearly lenacapavir may change the standard of HIV prevention for women
1小时前
求助中
Lenacapavir: an attractive option, but proceed with caution
9天前
已完结
Lenacapavir in first-line therapy
9天前
已完结
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
9天前
已完结
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
9天前
已完结
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
9天前
已完结
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA
9天前
已完结
Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion
9天前
已完结
皖公网安备34019202002308
